This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Evinacumab for homozygous familial hypercholesterolemia

< Back

Evinacumab for homozygous familial hypercholesterolemia


Endocrine, Nutritional and Metabolic

August 2019

Evinacumab is in clinical development for the treatment of homozygous familial hypercholesterolemia (HoFH). Familial hypercholestrolaemia (FH) is an inherited condition where a person’s cholesterol levels are higher than normal from birth as the liver is unable to break down or remove excess cholesterol. Specifically, FH patients have severe elevations in low density lipoprotein cholesterol (LDL-C) levels. This can lead to heart disease at a relatively young age. HoFH is a very rare and severe form of the disease which results from inheriting a faulty gene from both parents resulting in little or no LDL receptor activity. Treatment of hypercholesterolemia in patients with HoFH can be challenging with the current therapies and there is need for new treatments.
Evinacumab is a monoclonal antibody to angiopoietin-like protein 3 (ANGPTL3). ANGPTL3 is produced in the liver and regulates levels of triglycerides, LDL-C, and high-density lipoprotein cholesterol, in the blood. Evinacumab binds to and inhibits ANGPTL3 and lowers cholesterol thereby having the potential to reduce cardiovascular risk. Results from early studies have shown that evinacumab has the potential to result in clinically significant LDL-C reductions in HoFH patients.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts